



Presented by:
René Goehrum
President and CEO


Q1 2018 Results
May 30, 2018

This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements within the meaning of Canadian Securities legislation and the forward-looking statements contained herein are made as at the date of this presentation and, accordingly, are subject to change after such date. Undue reliance should not be placed on such statements. These statements involve a number of risks and uncertainties including statements regarding the outlook for BioSyent Inc., business and operational results.


By nature, these risks and uncertainties could cause actual results to differ materially from what has been indicated. Factors that could cause actual results to differ materially from any forward-looking statement include, but are not limited to, failure to obtain governmental regulatory approvals, product recalls, competition from similar products and other factors including those risks and uncertainties identified above.

BioSyent Inc. undertakes no obligation to update publicly or otherwise revise any forward-looking information as a result of new information, future results or other such factors which affect this information, except as required by law.

Sales, EBITDA and NIAT Quarter Ended March 31



Pharmaceutical Sales By Quarter



- **Q1 2018 pharmaceutical sales of \$4.3 million increased 19% over Q1 2017**
 - Q1 2018 Canadian pharmaceutical sales of \$3.8 million increased 12% over Q1 2017
 - Q1 2018 vs. Q1 2017 Canadian sales volumes (units):
 - FeraMAX[®] 150 +12%
 - FeraMAX[®] Powder +5%
 - RepaGyn[®] +21%
 - Cathejell[®] +22%
 - Q1 2018 International FeraMAX[®] sales of \$566k increased 90% over Q1 2017
 - Growing demand in international markets and repeat sales to largest customers
 - Quarterly variability in sales

- Long selling cycle, but more hospitals adopting Cysview®
- Implementation update
 - 6 hospital sites have adopted and ordered Cysview® - of which 4 hospitals placed first orders for Cysview® in April and May 2018
 - 7 additional hospitals have completed successful evaluations of Cysview® or intend to implement Cysview® and working through go-live planning
 - Evaluations underway or planned at 2 additional hospitals
- Q1 2018 financial results include Cysview® promotion expenses without revenue benefits (contribution margin)

CYSVIEW®
HEXAMINOLEVULINATE HCL



- **Atropine Sulphate re-launched Q1 2016**
 - Sales volumes (units) declined 12% in Q1 2018 vs. Q1 2017 due to pipelining in Q1 2017 for new accounts
 - Stronger Q2 2018 sales expected as a result of stock-out situation for competing products
- **Phenylephrine Hydrochloride launched Q4 2016**
 - Sales volumes (units) increased 17% in Q1 2018 vs. Q1 2017
- **136 Canadian hospitals have made repeat purchases of Aguettant System® PFS – launch thru April 30 this year**

- January 2018: Mr. Larry Andrews and Ms. Sara Elford appointed to Board of Directors (replacing Director retirements)
- May 2018: Mr. Joseph Arcuri elected to Board of Directors @ May 29, 2018 AGM (replacing Director retirement)
- May 2018: FeraMAX[®] named #1 recommended iron supplement brand in Canada for 3rd consecutive year



Growth driven by organic growth of existing portfolio **plus** incremental growth from new products and new international markets:

Existing product portfolio growth drivers

- FeraMAX[®]: Canada and International (existing markets)
- CYSVIEW[®]
- Cathejell[®] Jelly 2%
- RepaGyn[®]
- Aguettant System[®]

New products and new markets

- FeraMAX[®] International (Sales to new markets)
- 2 Cardiovascular Rx products; upon Health Canada approval
- Women's Health Rx product; upon Health Canada approval

New in-licensed products

- To be announced – active deal funnel
- Portfolio expansion – core to our strategy

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Financial Position

AS AT	March 31, 2018	December 31, 2017	% Change
ASSETS			
Trade and other receivables	\$ 2,200,887	\$ 2,236,695	-2%
Inventory	1,193,960	908,825	31%
Prepaid expenses and deposits	469,916	147,326	219%
Income tax recoverable	-	71,924	
Cash, cash equivalents and short-term investments	19,639,606	19,338,435	2%
Current Assets	23,504,369	22,703,205	4%
Equipment	288,382	290,926	-1%
Intangible assets	1,686,323	1,670,210	1%
Loans receivable	394,825	393,860	
Deferred tax asset	53,464	46,647	15%
TOTAL NON CURRENT ASSETS	2,422,994	2,401,643	1%
TOTAL ASSETS	\$ 25,927,363	\$ 25,104,848	3%
LIABILITIES AND SHAREHOLDERS' EQUITY			
Current liabilities	\$ 2,206,345	\$ 2,615,594	-16%
Deferred tax liability	284,765	276,327	3%
Long term debt	-	-	0%
Total Equity	23,436,253	22,212,927	6%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 25,927,363	\$ 25,104,848	3%


Working Capital of
 \$21.3 million
 +6% from Dec. 31, 2017

Cash and ST investments
 of \$19.6 million
 +2% from Dec. 31, 2017


Building Balance Sheet
 strength for deployment
 opportunities

Zero Debt

March 31 Cash Balance and Q1 Cash Generation (“CG”)



Return on Equity (“ROE”)



Quarter	NIAT	Diluted EPS	
Q1 2018	\$1,143,130	\$ 0.08	\$0.38
Q4 2017	\$1,457,228	\$ 0.10	
Q3 2017	\$1,294,575	\$ 0.09	
Q2 2017	\$1,552,918	\$ 0.11	
Q1 2017	\$ 901,556	\$ 0.06	\$0.29
Q4 2016	\$1,094,822	\$ 0.08	
Q3 2016	\$1,247,380	\$ 0.08	
Q2 2016	\$1,015,449	\$ 0.07	

TTM EPS Growth +31%



Stock Information

May 25, 2018

Exchange & Trading Symbol:
May 25, 2018 closing stock price (CAD)
52 Week Hi / Low:
Current Shares:
Warrants:
Options:
Fully Diluted:
P/E Ratio (TTM):
P/B Ratio:

TSXV: RX
\$10.10
\$7.42 / \$11.00
14,509,095
0
163,251
14,672,346
27.20
6.25

Thank you

www.BioSyent.com

www.sedar.com

www.tmxmoney.com

www.BioSyentPFS-System.ca

www.Cathejell.ca

www.CYSVIEW.ca

www.FeraMAX.com

www.Proktis-M.ca

www.RepaGyn.ca